Concepedia

G. Wilding

GW

Statistics

Publications

10

Citations

341

H-Index

10

Active since

1992

Affiliations

GlaxoSmithKline (United States)(Current)

Sarah Cannon

University of Wisconsin Carbone Cancer Center

G. Wilding is an author at GlaxoSmithKline (United States) specializing in cancer research, medicine, and oncology.

ORCID

Top concepts

Publications per year

1992–2011

10

Publications

10

Randomized Phase I Chemoprevention Dose-Seeking Study of  -Difluoromethylornithine

Richard R. Love, Paul P. Carbone, Ajit Kumar Verma et al. · JNCI Journal of the National Cancer Institute · 1993 · 87 citations

The importance of steroid hormones in prostate cancer.

G. Wilding · PubMed · 1992 · 83 citations

, , +12

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

William R. Schelman, Shahneen Sandhu, Víctor Moreno et al. · Journal of Clinical Oncology · 2011 · 57 citations

, , +16

Clinical activity of GW572016 in EGF10003 in patients with solid tumors

M. Versola, H. A. Burris, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2004 · 25 citations

, , +15

The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.

Eric J. Small, Geoffrey R. Weiss, Umekalsoom Malik et al. · PubMed · 1998 · 21 citations

1–5 of 10